Deerfield, IL, January 23, 2018 – Takeda Pharmaceuticals, U.S.A., Inc. (“Takeda”) announced today that a special “Putting Patients First” January issue of The American Journal of Gastroenterology published its analysis of patients with inflammatory bowel disease (IBD), which shows their highly personalized approach to choosing treatments. Takeda and Cedars-Sinai researchers conducted the study in two phases by first analyzing social media to understand what factors influence how patients with IBD seek treatment, and then fielding an adaptive choice-based survey to patients that ranks the importance of biologic attributes in their treatment decision-making. The survey results informed the development of an online tool that generates personalized discussion guides for patients to support shared decision-making when discussing treatment options with their provider. Through a grant from Takeda, Cedars-Sinai has since made the tool, called IBD&me (www.ibdandme.org), publicly available for any patient with IBD to use.
“Takeda is proud that Cedars-Sinai has made IBD&me available to any patient with IBD. It’s an innovative online tool that may help the IBD patient and provider communities as they evaluate which biologic treatment options are best for individuals,” said Karen Lasch, M.D., Medical Head, GI Specialty, U.S. Medical Office, Takeda. “We are committed to driving innovation within the digital space that will benefit the IBD community.”
Takeda Medical Affairs and researchers at Cedars-Sinai in Los Angeles began with an initial review of public online conversation among patients with ulcerative colitis (UC) and Crohn’s disease (CD). The social media analysis revealed a wide range of themes governing their experiences and choices with biologics, and a need for improved communication between patients and providers when discussing options. Common considerations included efficacy and safety profiles as well as overall experience with biologics and how they are administered.
The second step was to administer an adaptive choice-based survey to patients that ranks the importance of biologic attributes (e.g., efficacy, side-effect profile, mode of administration, mechanism of action) in decision-making. While averages showed slightly varied responses between patients with UC and CD, the results demonstrated that biologic decision-making is highly personalized, with close to 98 percent of 640 patients expressing unique decision-making profiles. The article detailing these results, titled “Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis,” was first published online in December 2017 and is in print this month in The American Journal of Gastroenterology.
Several effective biologic IBD therapies are currently available and have provided a range of important options that can improve disease management. However, in the absence of head-to-head trials, patients and their physicians often face challenges evaluating the complex differences between therapies and selecting one that fits their unique preferences due to a lack of comparative effectiveness data. IBD&me (www.ibdandme.org) was developed to help simplify that process. The online tool asks a series of questions to patients about what they prefer across a range of therapy attributes from method of delivery to the efficacy and safety profile and time between doses. The patients then receive a personalized report clearly outlining treatment factors they consider most important, which can be used in discussions with their physicians as they evaluate options.
“Digital health tools are becoming increasingly important in enabling healthcare providers to better understand their patients with IBD and provide personalized care, especially as more treatment options become available,” said Brennan Spiegel, M.D., Director, Health Services Research, Cedars-Sinai, Los Angeles, and principal investigator of the study. “IBD&me empowers patients with IBD by identifying what treatment attributes may be most important to them and supporting more open dialogue and shared decision-making with providers.”
About Ulcerative Colitis and Crohn’s Disease
Ulcerative colitis (UC) and Crohn’s disease (CD) are two of the most common forms of inflammatory bowel disease (IBD). Both UC and CD are chronic, relapsing, remitting, inflammatory conditions of the gastrointestinal (GI) tract that are often progressive in nature. UC only involves the large intestine as opposed to CD which can affect any part of the GI tract from mouth to anus. CD can also affect the entire thickness of the bowel wall, while UC only involves the innermost lining of the large intestine. UC often presents with symptoms of abdominal discomfort, loose bowel movements, including blood or pus. CD commonly presents with symptoms of abdominal pain, diarrhea and weight loss. The cause of UC or CD is not fully understood, however recent research suggests hereditary, genetics, environmental factors and/or an abnormal immune response to microbial antigens in genetically predisposed individuals can lead to UC or CD.
Takeda’s Commitment to Gastroenterology
Takeda is driven to improving the lives of patients with GI diseases through innovative medicines, dedicated patient disease management support and the evolution of the healthcare environment. Takeda is leading in gastroenterology through the delivery of innovative medicines. With more than 25 years of experience in this area, our broad approach to treating many diseases that impact the GI system and our global network of collaborators, Takeda aims to advance how patients manage their disease.
About Takeda Pharmaceuticals U.S.A., Inc.
Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.
The company has a commercial presence covering around 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Areas of R&D focus include central nervous system, cardiovascular and metabolic, gastroenterology, oncology, and vaccines.
Takeda Pharmaceuticals U.S.A., Inc. is located in Deerfield, Ill., and is the U.S. marketing and sales organization of Takeda Pharmaceutical Company Limited.
Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Pharmaceuticals U.S.A., Inc. is available through its website, www.takeda.us.
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Takeda’s growth is being fuelled by products, especially in oncology and gastroenterology, as well as its presence in emerging markets. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.
For more information, visit http://www.takeda.com/news.
Takeda Pharmaceuticals U.S.A., Inc.